01—Abstract
Summary
Summary of the 10-K filed February 15, 2019. Cited figures are marked; the original filing is the authoritative source.
IDEXX Laboratories' FY2018 10-K (filed February 15, 2019) shows a strong year of growth and profitability.
Revenue rose 12.4% reported (11.6% organic) to $2.213 billiona, driven by recurring diagnostic revenue, which accounted for about 75% of consolidated revenue. Recurring revenue growth was led by IDEXX VetLab consumables (up 19.0% reported) and reference laboratory services (up 13.1%). Gross margin expanded 40 basis points to 56.1%, and operating income grew 19.0% to $491.3 million, with operating margin reaching 22.2%.
Diluted EPS rose to $4.26b from $2.94, though the 2018 figure benefited from a lower effective tax rate of 17.6% (versus 30.9% in 2017), partly due to the 2017 Tax Act and share-based compensation tax benefits. The adoption of the New Revenue Standard (ASC 606) on January 1, 2018 materially affected reported results. Management attributed about $58.3 million of 2018 revenue and about $22.9 million of gross profit to the new standard, mainly from accelerated recognition of instrument revenue under the IDEXX 360 volume commitment and up-front loyalty programs.
Net income would have been about $18.1 millionc lower without the standard. Investors should therefore weigh the underlying organic growth rate more heavily than reported growth. The balance sheet remains highly leveraged, with stockholders' deficit of $9.2 million, driven by about $3.8 billion of cumulative share repurchases since 1999.
Total debt was about $1.0 billiond, including $398.9 million drawn on the $850 million revolver. Gross debt to Adjusted EBITDA was 1.67x and net debt to Adjusted EBITDA was 1.46x, comfortably under the 3.5x covenant.
Cash fell sharply to $123.8 million after $597.8 million of financing outflows, largely from debt repayment and $369 million of buybacks. Management guided to a 2019 capital expenditure plan of $160 million to $175 million, including headquarters expansion and a German lab relocation.
02—Key points
Key Highlights
- Revenue grew 12.4% reported and 11.6% organic to $2,213.2 million, with international sales at about 39% of revenue.
- Recurring diagnostic revenue reached about 75% of consolidated revenue, with IDEXX VetLab consumables up 19.0% and reference laboratory services up 13.1%.
- Operating income rose 19.0% to $491.3 million, and operating margin expanded to 22.2% from 21.0%.
- Diluted EPS increased to $4.26 from $2.94, helped by a 17.6% effective tax rate versus 30.9% in 2017.
- The New Revenue Standard added about $58.3 million to revenue and $18.1 million to net income in 2018, so underlying growth is somewhat lower than reported.
- Repurchased 1.77 million shares for $368.7 million; book equity remains negative at $(9.2) million due to buybacks.
- Leverage is moderate with gross debt to Adjusted EBITDA of 1.67x, versus a 3.5x covenant, but cash declined to $123.8 million after debt repayments.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2018, IDEXX Laboratories kept $0.17.
- Revenue$2.21B100.0%
- Cost of revenue−$971.7M43.9%
- Gross profit$1.24B56.1%
- Operating costs−$750.2M33.9%
- Operating income$491.3M22.2%
- Interest, other & tax−$114.3M5.2%
- Net income$377.0M17.0%
Where FY2018 revenue went
$2.21B- Cost of revenue: $971.7M, 44% of revenue
- Other operating costs: $632.3M, 29% of revenue
- Net income: $377.0M, 17% of revenue
- R&D: $117.9M, 5.3% of revenue
- Interest, other & tax: $114.3M, 5.2% of revenue
Kept 17% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2018filed February 15, 2019Financial Statements
FY2018 against FY2017
| Line item | FY2018FY2017 | Change |
|---|---|---|
| Revenue | $2.21B$1.97B | +12.4% |
| Cost of Revenue | $971.70M$871.68M | +11.5% |
| Gross Profit | $1.24B$1.10B | +13.1% |
| R&D Expenses | $117.86M$109.18M | +8.0% |
| Operating Expenses | $750.21M— | — |
| Operating Income | $491.33M$413.03M | +19.0% |
| Interest Expense | $34.74M$37.23M | −6.7% |
| Net Income | $377.03M$263.14M | +43.3% |
| EPS (Basic) | $4.34$3.00 | +44.7% |
| EPS (Diluted) | $4.26$2.94 | +44.9% |
| Shares Outstanding (Basic) | 86.86M87.77M | −1.0% |
| Shares Outstanding (Diluted) | 88.47M89.57M | −1.2% |
05—Questions
Frequently Asked Questions
How much of IDEXX's 2018 revenue growth came from the new revenue accounting standard rather than underlying business performance?
Management attributed approximately $58.3 million of 2018 revenue to the New Revenue Standard (ASC 606), out of total reported growth of $244.2 million. Excluding that amount, growth would have been roughly 9% rather than 12.4%. The adjustment mainly reflects accelerated recognition of instrument revenue under the IDEXX 360 volume commitment program and up-front loyalty programs, which shifts revenue earlier but does not change cash collected. Organic growth of 11.6% already excludes currency and acquisitions, but it still includes the accounting benefit.
Why is IDEXX's stockholders' equity negative, and does it signal financial distress?
The deficit of $(9.2) million is mainly the result of share repurchases, which have totaled about $3.8 billion since 1999 and are recorded as treasury stock. IDEXX has consistently returned excess cash to shareholders this way. A negative book value is common for companies with substantial buybacks and strong cash generation, and the company generated $400 million of operating cash flow in 2018. The negative equity is not a liquidity concern in itself, but it does mean the company relies on continued earnings and debt capacity to fund buybacks.
How exposed is IDEXX to currency movements and debt costs?
About 39% of revenue is generated outside the U.S. A 1% strengthening of the dollar would reduce 2019 revenue by about $8 million and operating income by about $4 million, based on the company's projections, and management expects a stronger dollar to reduce 2019 revenue by about $37 million. Hedging covers about 85% of intercompany product flows and is expected to offset about $11 million of operating profit. On debt, the $398.9 million revolver carries a weighted average rate of 3.63%, so a 1% rise in LIBOR would add about $4.0 million of annual interest expense.
What drove the sharp decline in IDEXX's cash balance and what is the 2019 capital plan?
Cash and equivalents fell to $123.8 million from $471.9 million (including marketable securities) at the end of 2017. The main driver was $597.8 million of financing outflows, including $256 million net repayment of the revolver and $369 million of share repurchases, funded partly by $284 million from liquidating marketable securities. For 2019, management expects capital expenditures of $160 million to $175 million, which includes the Westbrook, Maine headquarters expansion, relocation of the German core reference laboratory, and investments in manufacturing, software, and IT infrastructure.
06—Continue